BenevolentAI

BenevolentAI, founded in 2013, is a global leader in applying artificial intelligence (AI) to scientific innovation. The company focuses on using AI to unlock valuable data for advancing scientific knowledge. BenevolentAI operates through two key business units: BenevolentBio and BenevolentTech.

BenevolentBio uses the company’s AI technology to drive progress in human health and biosciences, while BenevolentTech is dedicated to refining the technology and expanding its application beyond healthcare. BenevolentAI's drug discovery efforts are central to its mission, with a diverse pipeline targeting various diseases, including atopic dermatitis, ulcerative colitis, amyotrophic lateral sclerosis (ALS), glioblastoma multiforme, inflammatory bowel disease, Parkinson’s disease, and others. These drug programs aim to address significant unmet medical needs in areas such as oncology, CNS diseases, and liver diseases, among others.

The company’s platform leverages a vast amount of biomedical information to support the development of new treatments. This AI-driven approach helps scientists design drugs with greater precision and efficiency, transforming the way treatments are developed. BenevolentAI operates in both the UK and the US, with its headquarters based in London.

In recent developments, BenevolentAI has undergone a strategic overhaul to refocus on its TechBio mission. The company is restructuring its organisational and budgetary plans to extend its operational runway into 2027. As part of this, BenevolentAI is also considering the possibility of delisting from Euronext Amsterdam to streamline its operations.

BenevolentAI was founded in 2013 in the United Kingdom by biotech entrepreneur Ken Mulvany. The company set out to apply artificial intelligence (AI) and machine learning to biomedical and life-science data, aiming to discover new treatments and scientific insights. In its early years, the company invested in building a knowledge graph and proprietary ontologies to represent relationships between genes, proteins, diseases, drugs, and other biomedical entities. BenevolentAI’s platform was designed to ingest structured and unstructured data, generate hypotheses for new targets, design molecules, and support drug discovery efforts.

In 2016–17, the firm began to attract significant external investment. For example, in 2017, it raised around £109.5 million at a valuation of about £1.4 billion, reflecting investor confidence in its AI-driven drug discovery model. At that time, the company marketed itself as a technology provider to major pharmaceutical companies, offering hypothesis generation and repositioning of known compounds, rather than initially developing all drugs in-house.

As the business evolved, BenevolentAI expanded its scope, building its own in-house drug discovery pipeline across a number of therapeutic areas. Its pipeline included programmes for atopic dermatitis (BEN2293), ulcerative colitis (BEN8744), amyotrophic lateral sclerosis (ALS) (BEN9160), glioblastoma multiforme, Parkinson’s disease, nonalcoholic steatohepatitis (NASH), chronic kidney disease, idiopathic pulmonary fibrosis, and others.

By the early 2020s, the company operated in both the UK and the US, headquartered in London with additional facilities. In May 2023, the company announced a strategic review and a new plan to reposition itself for a “new era in AI.” The plan included the launch of a new suite of AI products for biopharma partners, focusing on the commercial deployment of the platform technology, prioritising its most advanced drug assets (for example, BEN-8744 entering Phase 1 in Q3 2023 and BEN-28010 becoming IND-ready by Q4 2023), and reducing lab footprint and headcount to extend its cash runway.

In December 2024, BenevolentAI announced a major strategic overhaul, declaring a return to its original “TechBio” mission – refocusing on core technologies and innovation, rather than fully vertically integrated biopharma operations. The company indicated it would explore delisting from the Euronext Amsterdam exchange, restructure operations, and extend its cash runway into 2027. As of the present, the firm operates two distinct business units: one (BenevolentBio) applying its technology in human health and bioscience applications and another (BenevolentTech) building, refining, and commercialising the technology across wider domains. The platform remains centred on combining its knowledge graph, AI modelling, molecular design, and precision-medicine capabilities to assist in target identification, molecular design, and translational research.

BenevolentAI’s mission is to transform the drug discovery process by integrating artificial intelligence with scientific research. The company focuses on leveraging AI to unlock insights from vast amounts of biomedical data to design and develop new treatments. Its goal is to speed up the development of medicines for diseases with unmet medical needs. By using cutting-edge AI technologies, BenevolentAI aims to make drug discovery more efficient, precise, and accessible, helping to bring innovative treatments to patients faster and more effectively.

BenevolentAI envisions a future where AI drives breakthroughs in healthcare and biotechnology. The company aims to be a leader in applying artificial intelligence to biopharmaceuticals, enhancing the discovery of new medicines. BenevolentAI seeks to combine technology and science to create more personalised and effective treatments. The vision is to revolutionise drug development by making it faster, more precise, and tailored to individual needs, ultimately improving global healthcare outcomes. BenevolentAI is committed to using AI to solve complex medical challenges and contribute to a healthier world through advanced scientific innovations.

BenevolentAI has received notable recognition for its innovative approach to drug discovery and AI applications in biopharma. In 2017, the company was valued at £1.4 billion after securing significant investment, highlighting its potential in the AI and biotech sectors. It has earned accolades for its pioneering use of AI to unlock hidden biomedical knowledge and improve the efficiency of drug development. BenevolentAI’s platform has gained attention from major pharmaceutical companies and investors, cementing its reputation as a leader in TechBio. The company’s achievements reflect its commitment to transforming the healthcare landscape with AI-driven solutions.

BenevolentAI offers a range of products and services centred around artificial intelligence (AI) to accelerate drug discovery and improve biopharmaceutical development. The company’s AI-driven platform combines vast amounts of biomedical data with advanced machine learning algorithms to support researchers in designing and developing new medicines. The primary focus of BenevolentAI’s offerings is to make the drug development process more efficient, cost-effective, and precise.

One of the core services provided by BenevolentAI is its AI Platform. This platform integrates multiple technologies, including knowledge graphs, molecular design, and machine learning models, to generate insights that can drive the discovery of new drug candidates. It helps scientists understand complex biological systems by identifying relationships between genes, proteins, diseases, and existing drug compounds. The platform enables researchers to design targeted therapies and reposition existing drugs for new diseases. This accelerates the process of drug discovery, reducing the time and cost traditionally associated with developing new medicines.

BenevolentAI’s drug discovery services are aimed at addressing diseases with unmet medical needs. The company has developed a robust pipeline of drug candidates targeting various conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, glioblastoma multiforme, inflammatory bowel disease, and non-alcoholic steatohepatitis (NASH), among others. Through its AI platform, the company can identify promising drug candidates and optimise their development. BenevolentAI’s platform allows scientists to extract valuable insights from vast amounts of biomedical data, enabling the development of treatments with higher success rates.

The company also provides AI-powered drug repositioning services, where it uses its platform to identify new therapeutic uses for existing drugs. This approach can bring new treatments to market more quickly and with lower costs than traditional drug development, as it leverages already-approved compounds. By using AI to predict how these drugs might work in different conditions, BenevolentAI can significantly shorten the drug development timeline, offering an advantage in a competitive industry.

Another important offering from BenevolentAI is its customised research and development (R&D) solutions for biopharmaceutical companies. BenevolentAI partners with pharmaceutical companies to enhance their R&D processes. The company’s AI tools help these companies streamline their drug discovery pipeline, identify new targets for diseases, and improve the accuracy of their drug development efforts. BenevolentAI works closely with its partners to integrate its technology into their existing systems, making it easier for pharmaceutical companies to adopt AI in their drug discovery processes.

BenevolentAI’s BenevolentBio division focuses on applying AI to human health, with a particular emphasis on discovering new treatments for a wide range of diseases. This includes investigating conditions like chronic kidney disease, idiopathic pulmonary fibrosis, and cancer. The division is dedicated to using AI to discover and optimise new drug candidates, with a strong focus on rare and difficult-to-treat diseases.

On the technology side, BenevolentTech is responsible for refining and advancing the company’s AI technology. This division focuses on enhancing the capabilities of the company’s platform, ensuring it can be applied to a broad range of scientific and medical challenges. BenevolentTech works to expand the platform’s use beyond biopharma, exploring new sectors and applications for AI-driven innovation.